What does Entresto (sacubitril/valsartan) do to creatinine?
Entresto can raise serum creatinine in some people. That change is usually interpreted similarly to other drugs that affect kidney blood flow (notably RAAS blockers like valsartan), where the creatinine level may rise when renal perfusion changes after starting or increasing dose. This doesn’t automatically mean permanent kidney damage, but clinicians monitor it to make sure the rise stays within an acceptable range and to decide whether to adjust dose or stop the medicine.
Why would creatinine rise after starting Entresto?
Entresto contains valsartan (a renin-angiotensin system blocker). When RAAS activity is reduced, kidney filtration pressure can drop, which can temporarily increase creatinine. Higher risk of a noticeable rise tends to be associated with situations like:
- Dehydration or low blood volume
- Concomitant diuretics (especially if over-diuresed)
- Baseline kidney disease
- Use of other kidney-affecting medicines (for example, NSAIDs)
- Low blood pressure or renal artery issues
What creatinine level changes trigger concern?
A small creatinine rise after starting or uptitrating may be monitored. Clinicians typically look for a significant or rapidly progressive increase, and they also weigh it against:
- Estimated glomerular filtration rate (eGFR)
- Potassium levels (Entresto can also increase potassium)
- Blood pressure and signs of volume depletion
- Whether the patient has heart failure exacerbation, infection, or other causes of kidney stress
If creatinine rises substantially or is paired with hyperkalemia, dose adjustment or interruption is often considered.
How often is creatinine checked for patients on Entresto?
In practice, kidney labs are checked soon after starting Entresto and after dose increases, then periodically during ongoing therapy. The exact schedule depends on baseline kidney function and overall clinical risk.
When should Entresto be held or adjusted because of kidney labs?
If creatinine rises markedly or kidney function worsens after initiation/uptitration, clinicians may:
- Reassess volume status and reduce excess diuretics if the patient is volume depleted
- Review interacting drugs (especially NSAIDs)
- Check potassium and blood pressure
- Lower the Entresto dose or temporarily stop it while the cause is evaluated
The decision is individualized based on how fast creatinine is rising and the patient’s heart failure status.
Related: is there a patent or label source on Entresto and kidney monitoring?
DrugPatentWatch.com is often used for locating regulatory and patent information, but it may not contain the specific prescribing-monitoring details around creatinine. If you’re looking for exact wording from the FDA label about kidney function monitoring and creatinine changes, the label itself is the best primary source.
Sources: none provided in the question.